Last reviewed · How we verify
Eptifibatide facilitated PCI
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors during percutaneous coronary intervention.
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors during percutaneous coronary intervention. Used for Acute coronary syndrome undergoing percutaneous coronary intervention (PCI), Prevention of ischemic complications during PCI in high-risk patients.
At a glance
| Generic name | Eptifibatide facilitated PCI |
|---|---|
| Sponsor | Ottawa Heart Institute Research Corporation |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Eptifibatide is a cyclic heptapeptide that reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, inhibiting the final common pathway of platelet aggregation. By blocking fibrinogen and von Willebrand factor from cross-linking platelets, it reduces thrombotic complications during PCI procedures. The drug is administered intravenously as a bolus followed by infusion during the intervention.
Approved indications
- Acute coronary syndrome undergoing percutaneous coronary intervention (PCI)
- Prevention of ischemic complications during PCI in high-risk patients
Common side effects
- Bleeding (major and minor)
- Thrombocytopenia
- Hypotension
Key clinical trials
- Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |